Big Pharma has more money in its pocket for deals. And Big Pharma still needs more M&A for post-patent-cliff rebuilding. But Big Pharma's buyout targets want more money.
While Roche and Sanofi are expanding their investments in RNAi, Merck is getting out.
Montreal's JSS Medical Research has acquired competitor Integrated Research Inc., completing a deal the CRO says makes it the largest Canadian-owned contract researcher.
Adcock Ingram's takeover by Chile's CFR Pharmaceuticals may be stalled, but that hasn't stopped the South African drugmaker from moving forward with its own plans to double its sales from other countries on the African continent, a managing executive said Thursday.
Shire had hoped to pretty much have all of the shares of ViroPharma ($VPHM), the maker of rare disease drugs, pledged to its $4.2 billion buyout offer by the end of the year. But it didn't happen, and so it extended its $50 a share offer until last night. Now, it is extending the deadline again.
The mid-makeover Endo Health Solutions has found a buyer for the rest of its unwanted urology device business, selling HealthTronics to Altaris Capital Partners in a deal worth up to $130 million.
Italy's CROS NT has bought out MDSL International, absorbing the U.K. company's expertise in clinical data management, statistics and other biometrics services.
Endo Health Solutions thought it had made a deal for NuPathe. Just a few weeks ago, Endo CEO Rajiv De Silva announced the buyout, his third since taking the helm at the troubled drugmaker. But now, Teva Pharmaceutical Industries has swooped in with a higher bid.
Biologic drugs are becoming increasingly important in pharma portfolios, and South Korea's Celltrion is all about biologics. So it is no wonder if there is a behind-the-scenes bidding war going on to buy control of the company.
Forest Laboratories, hungry for sales to replace its flailing antidepressant Lexapro, has sewn up a $2.9 billion deal for the specialty drugmaker Aptalis. It's the latest move in a wham-bam series of changes designed to get Forest back on a profitable track.